摘要
目的探讨bcr—abl mRNA在慢性粒细胞白血病(CML)诊断、治疗及微小残留病变监测中的意义。方法采用实时定量聚合酶链反应(real—time PCR)方法检测324例CML患者518份标本的bcr—abl mRNA表达情况。结果CML慢性期、加速期和急变期患者的bcr-abl mRNA定量结果逐渐增高,分别为12.6%、25.4%和57.2%(P〈0.05)。异基因造血干细胞移植后的bcr—abl mRNA定量结果随时间延长逐渐降低,一般在移植6个月后转阴,服用伊马替尼(商品名:格列卫)与异基因造血干细胞移植病程相似,但融合基因转阴所用时间较长。结论real—time PCR检测bcr—abl mRNA对于诊断、评价疗效、监测微小残留病变以及预测疾病进展具有重要的临床应用价值。
Objective To evaluate significance of the quantification of bcr-abl mRNA in diagnosis and therapy of chronic myeloid leukemia (CML), essentiality significance for monitoring minimal residual disease. Methods Bcr-abl mRNA of 518 CML patients were detected using real-time PCR. Results Expression of bcr-abl mRNA was gradually increased among blastic phase (BP) (12.6 %), accelerated phase (AP) (25.4 %) and chronic phase (CP) (57.2 %) (P〈0.05). Quantification of ber-abl mRNA was cut down gradually after allotransplantation in the patients and becomes normal after treatment for 6 months. But quantification of ber-abl mRNA inpatients treated with imatinib mesylate became normal after 12 months. Conclusion Real-time PCR was reliable and can be used for diagnosis, monitoring the treatment outcome, detecting the minimal residual disease, and predicting blast crisis,
出处
《白血病.淋巴瘤》
CAS
2011年第6期345-346,349,共3页
Journal of Leukemia & Lymphoma
基金
河南省社会公益项目预研专项课题(072103810503)